Luca eolo Trodella

Nato a Roma il 01/12/1983. Laurea in Medicina e Chirurgia nel 2008. Specializzazione in Radioterapia Oncologica nel 2014. Dal 2014 al ad oggi dirigente medico presso il Policlinico Universitario Campus Bio-Medico di Roma

Principal investigator of ATLAS study: "A randomized double blind, placebo controlled fase III study of JNJ-56021927 in subjects with high risk, localized or locally advanced prostate cancer receiving treatment with primary radiation therapy".

Co-investigator of ABITUDE study: "A prospective observational study of patients with metastatic castration resistant prostate cancer progressing after standard hormonal therapy suitable for abiraterone acetate treatment – ABITUDE".

Co-investigator of Pros-IT CNR study “Progetto per il monitoraggio dei tumori della prostata in Italia”.

Membro di società scientifiche:

AIRO (Italian Association of Radiation Oncology),

SIUrO (Italian Society of Uro-Oncology)

Vicinanza et al. The psychological impact of the covid-19 pandemic on radiotherapy cancer patients.Transl Oncol. 2022 Aug;22:101457.

Mega et al. Early GLS changes detection after chemoradiation in locally advanced non-small cell lung cancer (NSCLC). Radiol Med. 2022 Dec;127(12):1355-1363.

Marvaso et al. The role of palliative radiotherapy in the management of elderly and frail patients with advanced bladder cancer: A survey by the AIRO uro-group Med Oncol 2021 Jan 23;38(2):14.

Francolini et al. Radiotherapy role in non-seminomatous germ cell tumors, radiobiological and technical issues of an unexplored scenario Int J Clin Oncol. 2021 Jul 17.

Antonelli et al. Overview of potential determinants of radical prostatectomy versus radiation therapy in management of clinically localized prostate cancer: results from an Italian, prospective, observational study (the Pros-IT CNR study) Minerva Urol Nefrol. 2020 Oct;72(5):595-604.

D'Angelillo et al. 18F-choline PET/CT driven salvage radiotherapy in prostate cancer patients: up-date analysis with 5-year median follow-up. Radiol Med. 2020 Jul;125(7):668-673.

Gacci et al. MIRROR-SIU/LUNA Study Group and the Pros-IT CNR Study Group World J Urol. 2021 May;39(5):1445-1452.

Buglione et al. Treatment paths for localised prostate cancer in Italy: The results of a multidisciplinary, observational, prospective study (Pros-IT CNR). PLoS One. 2019 Nov 1;14(11):e0224151.

Antonelli et al. Impact of Surgical Approach on Patient-Reported Outcomes after Radical Prostatectomy: A Propensity Score-Weighted Analysis from a Multicenter, Prospective, Observational Study (The Pros-IT CNR Study) Urol Int. 2019;103(1):8-18.

Porreca et al. Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study. Health Qual Life Outcomes. 2018 Jun 13;16(1):122.

Detti et al. Combining Abiraterone and Radiotherapy in Prostate Cancer Patients Who Progressed During Abiraterone Therapy. Anticancer Res. 2017 Jul;37(7):3717-3722

Fiore et al. Phase II study of induction chemotherapy followed by chemoradiotherapy in patients with borderline resectable and unresectable locally advanced pancreatic cancer. Sci Rep. 2017 Apr 5;7:45845.

Noale et al. Pros-IT CNR: an Italian prostate cancer monitoring project. Aging Clin Exp Res. 2017 Apr;29(2):165-172.

Fiore et al. Prospective study of cetuximab and gemcitabine in combination with radiation therapy: feasibility and efficacy in locally advanced pancreatic head cancer. Radiat Oncol. 2015 Dec 15;10:255

Infusino et al. Estimation of patient setup uncertainty using BrainLAB Exatrac X-Ray 6D system in image-guided radiotherapy. J Appl Clin Med Phys. 2015 Mar 8;16(2):5102

Minniti et al. Fractionated stereotactic radiosurgery for patients with brain metastases. J Neurooncol. 2014 Apr;117(2):295-301

D'Angelillo et al. Somatostatin analogs and disease control in castration-resistant prostate cancer: different biological behavior? Case series and review of the literature. Tumori. 2014 May-Jun;100(3):249-53

D'Angelillo et al. ¹⁸F-choline positron emission tomography/computed tomography-driven high-dose salvage radiation therapy in patients with biochemical progression after radical prostatectomy: feasibility study in 60 patients. Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):296-302

Ramella et al. A clinical score, including biohumoral parameters, is a useful pretest index to discriminate pulmonary infections from radiation damage in chemoradiation-treated lung cancer patients. Cancer Invest. 2014 May;32(4):110-4

Ramella et al. Chemoradiation for stage III non-small cell lung cancer. Eur J Oncol., vol. 18, n. 1, pp. 5-13, 2013

Ramella et al. The role of mammography after breast-conserving surgery and adjuvant chemotherapy. Tumori. 2013 Mar-Apr;99(2):199-203

Del Vescovo et al. MR imaging of rectal cancer before and after chemoradiation therapy. Radiol Med. 2012 Oct;117(7):1125-38